ZNF674 antisense RNA 1 (ZNF674-AS1)

ZNF674 antisense RNA 1 (ZNF674-AS1) is a long non-coding RNA gene located on the X chromosome (chrX:46,545,438-46,564,575 in GRCh38) and does not encode a protein[1][5]. ZNF674-AS1 is primarily studied for its regulatory role in cancer biology. It acts through epigenetic and post-transcriptional mechanisms, including interaction with proteins such as EZH2 and ALDOA, to modulate the expression of neighboring or pathway genes (notably CHST7), alter glycolytic metabolism, and influence cellular processes such as proliferation, apoptosis, migration, invasion, and drug resistance[2][4][6]. Its expression is frequently reduced in various cancers, and lower levels are associated with poorer prognosis and increased chemoresistance, especially to oxaliplatin in gastric cancer and to cisplatin in other tumor types[2][3][4]. Overexpression or restoration of ZNF674-AS1 resensitizes cancer cells to chemotherapy, suggesting its potential role as a biomarker for prognosis and therapy response, but it is not a classical therapeutic target or receptor in itself[2][3][4].

Other names

ZNF674 antisense RNA 1 (head to head)ZNF674 antisense RNA 1 (non-protein coding)ZNF674-AS1

Modulation of drug resistance through interaction with EZH2 and epigenetic silencing of CHST7 (linked to chemosensitivity in gastric cancer); Suppression of pyroptosis and promotion of cell proliferation affecting cisplatin sensitivity; Direct interaction with proteins such as EZH2 and ALDOA